financetom
Business
financetom
/
Business
/
Rep Data Acquires SightX to Deliver High-Speed, End-to-End Research Workflows With Built-In Response Quality
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rep Data Acquires SightX to Deliver High-Speed, End-to-End Research Workflows With Built-In Response Quality
Apr 14, 2026 6:06 AM

The combined offering enables a faster end-to-end research workflow, from survey programming to analytics, with quality controls embedded in the core

NEW ORLEANS, April 14, 2026 /PRNewswire/ -- Rep Data, a leading provider of full-service market research and data quality solutions, has acquired SightX, a next-gen, all-in-one consumer research platform. The acquisition creates a faster end-to-end research workflow with stronger quality controls embedded in the core, combining SightX's end-to-end research platform and analytics with Rep Data's response quality infrastructure.

Market research teams have relied on fragmented tools for survey programming, sampling, and data quality, creating delays and added complexity while still leaving room for fraud to impact results. Rep Data acquired SightX to change that, creating a single workflow that lets teams move faster, run research more frequently, and deliver results with confidence.

"Researchers have been forced to choose between speed and confidence for too long," said Patrick Stokes, CEO and Founder of Rep Data. "This acquisition brings those together in a single workflow. SightX gives teams a faster path from survey build to results, and Rep Data helps ensure the data behind those results is real, defensible, and ready to act on."

"The best research changes how companies think, how products are built, and how markets evolve," said Tim Lawton, Co-Founder and Co-CEO of SightX. "This integrated offering makes research not only accessible, but trustworthy. Being part of Rep Data allows us to deliver on that promise at scale."

Any survey programmed or analyzed in SightX will now benefit from Rep Data's quality infrastructure, helping block low-quality traffic identified by ReDem and more sophisticated fraud identified by Research Defender.

What Rep Data acquiring SightX means for researchers:

Single workflow: programming, fielding, supply, quality controls, and analytics in one platformReduced fragmentation: fewer handoffs across vendors and tools, with less integration setupEmbedded quality controls: preferred panels configured with Research Defender and ReDemThe broader goal is to move research teams beyond a fragmented model of separate programming tools, preferred sample vendors, bolt-on fraud tools, and heavy post-field cleanup.

Rep Data believes strong findings depend on more than sample size and statistical significance. If respondents are not real, not representative, or not paying attention, the data breaks down fast. This acquisition is intended to help researchers maintain the quality of each "n" in the dataset, enabling them to present results with greater confidence.

"Researchers don't need more tools, they need a single workflow they can trust to get the job done right, and on time," Stokes added. "That's what we're giving them."

About Rep Data

Rep Data provides full-service data collection solutions for researchers, helping expedite data collection for primary quantitative research studies, with a hyper-focus on data quality and consistent execution. Backed by Mountaingate Capital, a growth-focused private equity investment firm, Rep Data is on a mission to be a reliable, repeatable data collection partner for approximately 500 clients, including market research agencies, management consultancies, Fortune 500 corporations, advertising agencies, brand strategy consultancies, universities, communications agencies, public relations firms, and more. www.repdata.com

Media Contact: Troy Harrington, [email protected], +1-714-767-9671

View original content to download multimedia:https://www.prnewswire.com/news-releases/rep-data-acquires-sightx-to-deliver-high-speed-end-to-end-research-workflows-with-built-in-response-quality-302741374.html

SOURCE Rep Data

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MDA Space Prices IPO In the U.S.
MDA Space Prices IPO In the U.S.
Mar 12, 2026
06:28 AM EDT, 03/12/2026 (MT Newswires) -- MDA Space ( MDA ) overnight Wednesday announced the pricing of its previously announced marketed public offering of common shares in the United States and Canada. A statement noted the underwriters have agreed to purchase 9,836,065 common shares from the company in the offering at a price of US$30.50 per share, for aggregate...
BRIEF-Summit Royalties Announces Agreement to Acquire Royalty on Newmont's Saddle North Deposit
BRIEF-Summit Royalties Announces Agreement to Acquire Royalty on Newmont's Saddle North Deposit
Mar 12, 2026
March 12 (Reuters) - Summit Royalties Ltd ( SUMMF ): * SUMMIT ROYALTIES ANNOUNCES AGREEMENT TO ACQUIRE ROYALTY ON NEWMONT'S SADDLE NORTH DEPOSIT * SUMMIT ROYALTIES LTD ( SUMMF ) - TO BUY 1.0% NSR ROYALTY ON SADDLE NORTH FROM NEWMONT FOR C$5 MILLION IN SHARES * SUMMIT ROYALTIES LTD ( SUMMF ) - CONSIDERATION IS 2.8 MILLION SUMMIT SHARES...
Market Chatter: Caesars Entertainment in $7 Billion Takeover Deal Talks With Tilman Fertitta
Market Chatter: Caesars Entertainment in $7 Billion Takeover Deal Talks With Tilman Fertitta
Mar 12, 2026
06:28 AM EDT, 03/12/2026 (MT Newswires) -- Caesars Entertainment ( CZR ) has been in exclusive takeover discussions with Tilman Fertitta for about $7 billion after the billionaire topped a competing offer from Icahn Enterprises ( IEP ) for the betting company, The Wall Street Journal reported Wednesday, citing people familiar with the matter. Fertitta Entertainment has been discussing paying...
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases
Gyre Therapeutics Swings to Net Loss in Q4, Revenue Increases
Mar 12, 2026
06:28 AM EDT, 03/12/2026 (MT Newswires) -- Gyre Therapeutics ( GYRE ) reported a Q4 net loss Thursday of $0.02 per diluted share, compared with breakeven a year earlier. Three analysts polled by FactSet expected earnings of $0.06 per share. Revenue for the quarter ended Dec. 31 was $37.2 million, up from $27.9 million a year earlier. Three analysts surveyed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved